Pruritus Clinical Trial
Background: Uremic pruritus is one of the common complications in long-term dialysis
patients. In general, many factors including xerosis, elevated serum calcium, phosphate,
calcium-phosphate product, hyperparathyroidism and inadequate dialysis may contribute to it.
Recently, researchers reported that immuno-hypothesis with high serum level of cytokines
could be the cause of uremic pruritus. Polymethylmethacrylate (PMMA) artificial kidney (AK)
has been reported to adsorb more serum cytokines than other high flux artificial kidneys.
Methods: In July 2006, 30 patients with severe uremic pruritus from 300 chronic hemodialysis
patients in a single center entered this prospective study. Their dialyzers were changed to
PMMA AK for 4 weeks. The severity of pruritus was evaluated every week using the results of
a questionnaire (pruritus score). Laboratory assays including pre-dialysis serum blood urea
nitrogen, creatinine, β2-microgblubulin (β2M), calcium, phosphate, intact parathyroid
hormone (iPTH), total CO2, ferritin, hematocrit, high sensitivity C-reactive protein
(hsCRP), IL-1, IL-2, IL-6, IL-18, TNF-α, KT/V and β2M clearance were measured before and at
the end of 4 weeks of PMMA AK use.
Expected Results:To prove the PMMA membrane could improve the uremic pruritus and to reveal
the effect of PMMA membrane on serum level of possible factors contributing to uremic
pruritus.
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
| Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
| Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
| Terminated |
NCT01825655 -
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
|
Phase 4 | |
| Completed |
NCT01236859 -
Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus
|
N/A | |
| Completed |
NCT00782054 -
Evaluation of Post Burn Rehabilitation Population for Itch Control
|
Phase 4 | |
| Completed |
NCT04999787 -
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
|
Phase 2 | |
| Recruiting |
NCT04256759 -
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
|
Phase 2 | |
| Completed |
NCT04337073 -
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus
|
Early Phase 1 | |
| Completed |
NCT04415034 -
Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
|
||
| Active, not recruiting |
NCT05525520 -
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
|
Phase 2 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Completed |
NCT04399525 -
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
|
N/A | |
| Recruiting |
NCT02432508 -
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
|
N/A | |
| Completed |
NCT02653703 -
L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain
|
N/A | |
| Completed |
NCT01963793 -
Topical Aprepitant in Prurigo Patients
|
Phase 2 | |
| Completed |
NCT01232985 -
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
|
Phase 2 | |
| Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
| Recruiting |
NCT06120907 -
Swiss Itch Registry
|
||
| Recruiting |
NCT04589429 -
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
|
Phase 2 |